From the 4C, IHL are spending more on admin and staff cost than they are investing in R&D. They also estimate this quarter will be similar to the last. They'll need to splash out in Q2 to fund a clinical trial though.
IHL Price at posting:
6.0¢ Sentiment: None Disclosure: Not Held
